According to Atara Biotherapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.226547. At the end of 2022 the company had a P/E ratio of -1.47.
Year | P/E ratio | Change |
---|---|---|
2022 | -1.47 | -66.12% |
2021 | -4.34 | -6.89% |
2020 | -4.66 | 61.65% |
2019 | -2.88 | -56.49% |
2018 | -6.63 | 46.15% |
2017 | -4.54 | -12.15% |
2016 | -5.16 | -56.59% |
2015 | -11.9 | -23.38% |
2014 | -15.5 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
ImmunoGen
IMGN | -101 | 44,368.48% | ๐บ๐ธ USA |
Agenus
AGEN | -15.2 | 6,625.01% | ๐บ๐ธ USA |
Affimed
AFMD | -6.95 | 2,967.14% | ๐ฉ๐ช Germany |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.